Regado Biosciences, Inc., a Basking Ridge, New Jersey-based developer of antithrombotic aptamers with active control agents, has secured $51m in Series E financing.
The round was led by new investor RusnanoMedInvest, a subsidiary of the state-run Russian investment firm RUSNANO, with participation from Baxter Ventures, Edmond de Rothschild Investment Partners, Domain Associates, Quaker Partners, Aurora Funds and Caxton Advantage Life Sciences Fund.
The company intends to use the capital for its “REGULATE – PCI” Phase 3 clinical study of REG1 for use in percutaneous coronary intervention (PCI) in the acute coronary syndrome (ACS) population. Regado is also pursuing an additional parallel development program for REG1 for use in TAVI (transaortic valve implantation) and REG3 in diabetic vasculopathy.
Led by David J. Mazzo , PhD, President and CEO, the company has a lab facility in Durham, NC.